Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (1)
  • Autophagy
    (1)
  • PD-1/PD-L1
    (1)
  • TNF
    (1)
  • Others
    (1)
Filter
Search Result
Results for "

atezolizumab

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    2
    TargetMol | Inhibitors_Agonists
  • Inhibitory Antibodies
    3
    TargetMol | Inhibitory_Antibodies
Atezolizumab
T99021380723-44-3
Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
TargetMol
RO7567132
RO 7567132, RG6221, RG 6221, FAP-LTBR, FAPLTBR
T9901A-748
RO7567132 (FAP-LTBR) is a novel bispecific antibody that binds and agonizes LTBR bivalently while binds and antagonizes FAP monovalently, thereby limiting the activation of LTBR to the tumor microenvironment, inducing the formation of local tertiary lymphoid structures (TLS), and reducing systemic toxicity. Its mouse alternative can inhibit breast cancer growth, and the effect is better when combined with atezolizumab. In the mouse colorectal cancer model, it can also enhance immune cell infiltration and TLS-like structure formation.
  • Inquiry Price
Size
QTY
Tiragolumab
RO 7092284, RG6058-11, RG6058-10, RG-6058, MTIG-7192A
T353921918185-84-8
Tiragolumab(MTIG-7192A) is a monoclonal antibody that targets T-cell immunoglobulin and the ITIM structural domain (TIGIT).Tiragolumab is often used in combination with the PD-L1 inhibitor, Atezolizumab, for the treatment of solid malignant tumors such as non-small cell lung cancer.
  • Inquiry Price
Size
QTY